

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

Obesity is globally prevalent and highly heritable, but its underlying genetic factors remain largely elusive. To identify genetic loci for obesity susceptibility, we examined associations between body mass index and ~2.8 million SNPs in up to 123,865 individuals with targeted follow up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity susceptibility loci and identified 18 new loci associated with body mass index ($P < 5 \times 10^{-8}$), one of which includes a copy number variant near *GPRC5B*. Some loci (at *MC4R*, *POMC*, *SH2B1* and *BDNF*) map near key hypothalamic regulators of energy balance, and one of these loci is near *GIPR*, an incretin receptor. Furthermore, genes in other newly associated loci may provide new insights into human body weight regulation.

Obesity is a major and increasingly prevalent risk factor for multiple disorders, including type 2 diabetes and cardiovascular disease^{1,2}. Although lifestyle changes have driven its prevalence to epidemic proportions, heritability studies provide evidence for a substantial genetic contribution (with heritability estimates (h^2) of ~40%–70%) to obesity risk^{3,4}. BMI is an inexpensive, non-invasive measure of obesity that predicts the risk of related complications⁵. Identifying genetic determinants of BMI could lead to a better understanding of the biological basis of obesity.

Genome-wide association studies (GWAS) of BMI have previously identified ten loci with genome-wide significant ($P < 5 \times 10^{-8}$) associations^{6–10} in or near *FTO*, *MC4R*, *TMEM18*, *GNPDA2*, *BDNF*, *NEGR1*, *SH2B1*, *ETV5*, *MTCH2* and *KCTD15*. Many of these genes are expressed or known to act in the central nervous system, highlighting a likely neuronal component in the predisposition to obesity⁹. This pattern is consistent with results in animal models and studies of monogenic human obesity in which neuronal genes, particularly those expressed in the hypothalamus and involved in regulation of appetite or energy balance, are known to play a major role in susceptibility to obesity^{11–13}.

The ten previously identified loci account for only a small fraction of the variation in BMI. Furthermore, power calculations based on the effect sizes of established variants have suggested that increasing the sample size would likely lead to the discovery of additional variants⁹. To identify additional loci associated with BMI, we expanded the Genetic Investigation of Anthropometric Traits (GIANT) Consortium genome-wide association meta-analysis to include a total of 249,796 individuals of European ancestry.

RESULTS

Stage 1 GWAS identifies new loci associated with BMI

We first conducted a meta-analysis of GWAS of BMI and ~2.8 million imputed or genotyped SNPs using data from 46 studies including up to 123,865 individuals (Online Methods, **Supplementary Fig. 1** and **Supplementary Note**). This stage 1 analysis revealed

19 loci associated with BMI at $P < 5 \times 10^{-8}$ (**Table 1**, **Fig. 1a** and **Supplementary Table 1**). These 19 loci included all ten loci from previous GWAS of BMI^{6–10}, two loci previously associated with body weight¹⁰ (at *FAIM2* and *SEC16B*) and one locus previously associated with waist circumference¹⁴ (near *TFAP2B*). The remaining six loci, near *GPRC5B*, *MAP2K5-LBXCOR1*, *TNNI3K*, *LRRN6C*, *FLJ35779-HMGR* and *PRKD1*, have not previously been associated with BMI or other obesity-related traits.

Stage 2 follow up identifies additional new loci for BMI

To identify additional BMI-associated loci and to validate the loci that reached genome-wide significance in the stage 1 analyses, we examined SNPs representing 42 independent loci (including the 19 genome-wide significant loci) having a stage 1 $P < 5 \times 10^{-6}$. Variants were considered to be independent if the pair-wise linkage disequilibrium (LD, r^2) was less than 0.1 and if they were separated by at least 1 Mb. In stage 2, we examined these 42 SNPs in up to 125,931 additional individuals (79,561 newly genotyped individuals from 16 different studies and 46,370 individuals from 18 additional studies for which genome-wide association data were available; **Table 1**, **Supplementary Note** and Online Methods). In a joint analysis of stage 1 and stage 2 results, 32 of the 42 SNPs reached $P < 5 \times 10^{-8}$ (**Table 1**, **Supplementary Table 1** and **Supplementary Figs. 1** and **2**). Even after excluding SNPs within the 32 confirmed BMI loci, we still observed an excess of small P values compared to the distribution expected under the null hypothesis (**Fig. 1b** and **Supplementary Fig. 3**), suggesting that more BMI loci remain to be uncovered.

The 32 confirmed associations included all 19 loci with $P < 5 \times 10^{-8}$ at stage 1, 12 additional new loci near *RBJ-ADCY3-POMC*, *QPCTL-GIPR*, *SLC39A8*, *TMEM160*, *FANCL*, *CADM2*, *LRP1B*, *PTBP2*, *MTIF3-GTF3A*, *ZNF608*, *RPL27A-TUB* and *NUDT3-HMGA1* and one locus (in *NRXN3*) previously associated with waist circumference¹⁵ (**Table 1**, **Supplementary Table 1** and **Supplementary Figs. 1** and **2**). In all, our study increased the number of loci robustly associated with BMI from 10 to 32. Four of the 22 new loci were previously associated

A full list of authors and affiliations appear at the end of the paper.

Received 13 May; accepted 15 September; published online 10 October 2010; doi:10.1038/ng.686

with body weight¹⁰ or waist circumference^{14,15}, whereas 18 new loci had not previously associated with any obesity-related trait in the general population. Although we confirmed all loci previously established by large-scale GWAS for BMI⁶⁻¹⁰ and waist circumference^{14,15}, four

loci previously identified in GWAS for early-onset or adult morbid obesity^{16,17} (at *NPC1*, rs1805081, $P = 0.0025$; *MAF*, rs1424233, $P = 0.25$; *PTER*, rs10508503, $P = 0.64$; and *TNKS-MSRA*, rs473034, $P = 0.23$) showed limited or no evidence of association with BMI in our study.

Table 1 Stage 1 and stage 2 results of the 32 SNPs that were associated with BMI at genome-wide significant ($P < 5 \times 10^{-8}$) levels

SNP	Nearest gene	Other nearby genes ^a	Chr.	Position ^b (bp)	Alleles ^b		Frequency effect allele	Per allele change in BMI β (s.e.m.) ^c	Explained variance (%)	Stage 1 P	Stage 2 P	Stage 1 + 2	
					Effect	Other						n	P
Previously identified BMI loci													
rs1558902	<i>FTO</i>		16	52,361,075	A	T	0.42	0.39 (0.02)	0.34%	2.05×10^{-62}	1.01×10^{-60}	192,344	4.8×10^{-120}
rs2867125	<i>TMEM18</i>		2	612,827	C	T	0.83	0.31 (0.03)	0.15%	2.42×10^{-22}	4.42×10^{-30}	197,806	2.77×10^{-49}
rs571312	<i>MC4R</i> (B)		18	55,990,749	A	C	0.24	0.23 (0.03)	0.10%	1.82×10^{-22}	3.19×10^{-21}	203,600	6.43×10^{-42}
rs10938397	<i>GNPDA2</i>		4	44,877,284	G	A	0.43	0.18 (0.02)	0.08%	4.35×10^{-17}	1.45×10^{-15}	197,008	3.78×10^{-31}
rs10767664	<i>BDNF</i> (B,M)		11	27,682,562	A	T	0.78	0.19 (0.03)	0.07%	5.53×10^{-13}	1.17×10^{-14}	204,158	4.69×10^{-26}
rs2815752	<i>NEGR1</i> (C,Q)		1	72,585,028	A	G	0.61	0.13 (0.02)	0.04%	1.17×10^{-14}	2.29×10^{-9}	198,380	1.61×10^{-22}
rs7359397	<i>SH2B1</i> (Q,B,M)	<i>APOB48R</i> (Q,M), <i>SULT1A2</i> (Q,M), <i>AC138894.2</i> (M), <i>ATXN2L</i> (M), <i>TUFM</i> (Q)	16	28,793,160	T	C	0.40	0.15 (0.02)	0.05%	1.75×10^{-10}	7.89×10^{-12}	204,309	1.88×10^{-20}
rs9816226	<i>ETV5</i>		3	187,317,193	T	A	0.82	0.14 (0.03)	0.03%	7.61×10^{-14}	1.15×10^{-6}	196,221	1.69×10^{-18}
rs3817334	<i>MTCH2</i> (Q,M)	<i>NDUFS3</i> (Q), <i>CUGBP1</i> (Q)	11	47,607,569	T	C	0.41	0.06 (0.02)	0.01%	4.79×10^{-11}	1.10×10^{-3}	191,943	1.59×10^{-12}
rs29941	<i>KCTD15</i>		19	39,001,372	G	A	0.67	0.06 (0.02)	0.00%	1.31×10^{-9}	2.40×10^{-2}	192,872	3.01×10^{-9}
Previously identified waist and weight loci													
rs543874	<i>SEC16B</i>		1	176,156,103	G	A	0.19	0.22 (0.03)	0.07%	1.66×10^{-13}	2.41×10^{-11}	179,414	3.56×10^{-23}
rs987237	<i>TFAP2B</i>		6	50,911,009	G	A	0.18	0.13 (0.03)	0.03%	5.97×10^{-16}	2.40×10^{-6}	195,776	2.90×10^{-20}
rs7138803	<i>FAIM2</i>		12	48,533,735	A	G	0.38	0.12 (0.02)	0.04%	3.96×10^{-11}	7.82×10^{-8}	200,064	1.82×10^{-17}
rs10150332	<i>NRXN3</i>		14	79,006,717	C	T	0.21	0.13 (0.03)	0.02%	2.03×10^{-7}	2.86×10^{-5}	183,022	2.75×10^{-11}
Newly identified BMI loci													
rs713586	<i>RBJ</i>	<i>ADCY3</i> (Q, M), <i>POMC</i> (Q,B)	2	25,011,512	C	T	0.47	0.14 (0.02)	0.06%	1.80×10^{-7}	1.44×10^{-16}	230,748	6.17×10^{-22}
rs12444979	<i>GPRC5B</i> (C,Q)	<i>IQCK</i> (Q)	16	19,841,101	C	T	0.87	0.17 (0.03)	0.04%	4.20×10^{-11}	8.13×10^{-12}	239,715	2.91×10^{-21}
rs2241423	<i>MAP2K5</i>	<i>LBXCOR1</i> (M)	15	65,873,892	G	A	0.78	0.13 (0.02)	0.03%	1.15×10^{-10}	1.59×10^{-9}	227,950	1.19×10^{-18}
rs2287019	<i>QPCTL</i>	<i>GIPR</i> (B,M)	19	50,894,012	C	T	0.80	0.15 (0.03)	0.04%	3.18×10^{-7}	1.40×10^{-10}	194,564	1.88×10^{-16}
rs1514175	<i>TNNI3K</i>		1	74,764,232	A	G	0.43	0.07 (0.02)	0.02%	1.36×10^{-9}	7.04×10^{-6}	227,900	8.16×10^{-14}
rs13107325	<i>SLC39A8</i> (Q,M)		4	103,407,732	T	C	0.07	0.19 (0.04)	0.03%	1.37×10^{-7}	1.93×10^{-7}	245,378	1.50×10^{-13}
rs2112347	<i>FLJ35779</i> (M)	<i>HMGCR</i> (B)	5	75,050,998	T	G	0.63	0.10 (0.02)	0.02%	4.76×10^{-8}	8.29×10^{-7}	231,729	2.17×10^{-13}
rs10968576	<i>LRRN6C</i>		9	28,404,339	G	A	0.31	0.11 (0.02)	0.02%	1.88×10^{-8}	3.19×10^{-6}	216,916	2.65×10^{-13}
rs3810291	<i>TMEM160</i> (Q)	<i>ZC3H4</i> (Q)	19	52,260,843	A	G	0.67	0.09 (0.02)	0.02%	1.04×10^{-7}	1.59×10^{-6}	233,512	1.64×10^{-12}
rs887912	<i>FANCL</i>		2	59,156,381	T	C	0.29	0.10 (0.02)	0.03%	2.69×10^{-6}	1.72×10^{-7}	242,807	1.79×10^{-12}
rs13078807	<i>CADM2</i>		3	85,966,840	G	A	0.20	0.10 (0.02)	0.02%	9.81×10^{-8}	5.32×10^{-5}	237,404	3.94×10^{-11}
rs11847697	<i>PRKD1</i>		14	29,584,863	T	C	0.04	0.17 (0.05)	0.01%	1.11×10^{-8}	2.25×10^{-4}	241,667	5.76×10^{-11}
rs2890652	<i>LRP1B</i>		2	142,676,401	C	T	0.18	0.09 (0.03)	0.02%	2.38×10^{-7}	9.47×10^{-5}	209,068	1.35×10^{-10}
rs1555543	<i>PTBP2</i>		1	96,717,385	C	A	0.59	0.06 (0.02)	0.01%	7.65×10^{-7}	4.48×10^{-5}	243,013	3.68×10^{-10}
rs4771122	<i>MTIF3</i>	<i>GTF3A</i> (Q)	13	26,918,180	G	A	0.24	0.09 (0.03)	0.02%	1.20×10^{-7}	8.24×10^{-4}	198,577	9.48×10^{-10}
rs4836133	<i>ZNF608</i>		5	124,360,002	A	C	0.48	0.07 (0.02)	0.01%	7.04×10^{-7}	1.88×10^{-4}	241,999	1.97×10^{-9}
rs4929949	<i>RPL27A</i>	<i>TUB</i> (B)	11	8,561,169	C	T	0.52	0.06 (0.02)	0.01%	7.57×10^{-8}	1.00×10^{-3}	249,791	2.80×10^{-9}
rs206936	<i>NUDT3</i>	<i>HMGAI</i> (B)	6	34,410,847	G	A	0.21	0.06 (0.02)	0.01%	2.81×10^{-6}	7.39×10^{-4}	249,777	3.02×10^{-8}


Chr., chromosome; Q, association and eQTL data converge to affect gene expression; B, biological candidate; M, BMI-associated variant is in strong LD ($r^2 \geq 0.75$) with a missense variant in the indicated gene; C, CNV.

^aGenes within ± 500 kb of the lead SNP. ^bPositions according to Build 36 and allele coding based on the positive strand. ^cEffect sizes in kg/m^2 obtained from stage 2 cohorts only.



Figure 1 Genome-wide association results for the BMI meta-analysis. (a) Manhattan plot showing the significance of association between all SNPs and BMI in the stage 1 meta-analysis, highlighting SNPs previously reported to show genome-wide significant association with BMI (blue), waist or waist circumference (green) and the 18 new regions described here (red). The 19 SNPs that reached genome-wide significance in stage 1 (13 previously reported and 6 new SNPs) are listed in **Table 1**.

(b) Quantile-quantile plot of SNPs in the stage 1 meta-analysis (black) and after removing any SNPs within 1 Mb of the ten previously reported genome-wide significant hits for BMI (blue), after additionally excluding SNPs from the four loci for waist or weight (green), and after excluding SNPs from all 32 confirmed loci (red). The plot is abridged at the y axis (at $P < 10^{-20}$) to better visualize the excess of small P values after excluding the 32 confirmed loci (**Supplementary Fig. 3** shows the full-scale quantile-quantile plot). The shaded region is the 95% concentration band. (c) Plot of effect size (in inverse-normally transformed units (invBMI)) versus effect-allele frequency of newly identified and previously identified BMI variants after stage 1 and stage 2 meta-analysis, including the 10 previously identified BMI loci (blue), the 4 previously identified waist and weight loci (green) and the 18 newly identified BMI loci (red). The dotted lines represent the minimum effect sizes that could be identified for a given effect-allele frequency with 80% (upper line), 50% (middle line) and 10% (lower line) power, assuming a sample size of 123,000 individuals and an α level of 5×10^{-8} .



As could be expected, the effect sizes of the 18 newly discovered loci are slightly smaller, for a given minor allele frequency, than those of the previously identified variants (**Table 1** and **Fig. 1c**). The increased sample size used here also brought out more signals with low minor allele frequency. The BMI-increasing allele frequencies for the 18 newly identified variants ranged from 4% to 87%, covering more of the allele frequency spectrum than previous, smaller GWAS of BMI (24%–83%)^{9,10} (**Table 1** and **Fig. 1c**).

We tested for evidence of non-additive (dominant or recessive) effects, SNP \times SNP interaction effects and heterogeneity by sex or study among the 32 BMI-associated SNPs (Online Methods). We found no evidence for any such effects (all $P > 0.001$ and no significant results were seen after correcting for multiple testing) (**Supplementary Table 1** and **Supplementary Note**).


Impact of the 32 confirmed loci on BMI, obesity, body size and other metabolic traits

Together, the 32 confirmed BMI loci explained 1.45% of the inter-individual variation in BMI in the stage 2 samples, with the *FTO* SNP accounting for the largest proportion of the variance (0.34%) (**Table 1**). To estimate the cumulative effect of the 32 variants on BMI, we constructed a genetic susceptibility score that summed the number of BMI-increasing alleles weighted by the overall stage 2 effect sizes in the Atherosclerosis Risk in Communities (ARIC) study ($n = 8,120$), one of our largest population-based studies (Online Methods). For each unit increase in the genetic-susceptibility score, which is approximately equivalent to having one additional risk allele, BMI increased by 0.17 kg/m², the equivalent of a 435–551 g gain in body weight in adults of 160–180 cm in height. The difference in average BMI between individuals with a high genetic-susceptibility score (defined as having ≥ 38 BMI-increasing alleles, comprising 1.5% ($n = 124$) of the ARIC sample) and those with a low genetic-susceptibility score (defined as having ≤ 21 BMI-increasing alleles, comprising 2.2% ($n = 175$) of

the ARIC sample) was 2.73 kg/m², equivalent to a 6.99–8.85 kg body weight difference in adults of 160–180 cm in height (**Fig. 2a**). Still, we note that the predictive value for obesity risk and BMI of the 32 variants combined was modest, although it was statistically significant (**Fig. 2b** and **Supplementary Fig. 4**). The area under the receiver-operating characteristic (ROC) curve for prediction of risk of obesity (BMI ≥ 30 kg/m²) using a model including age, age² and sex only was 0.515 ($P = 0.023$ compared to the area under the curve (AUC) of 0.50), which increased to 0.575 ($P < 10^{-5}$) when the 32 confirmed SNPs were also included in the model (**Fig. 2b**). The area under the ROC curve for the model including the 32 SNPs only was 0.574 ($P < 10^{-5}$).

All 32 confirmed BMI-increasing alleles showed directionally consistent effects on the risk of being overweight (BMI ≥ 25 kg/m²) or obese (BMI ≥ 30 kg/m²) in the stage 2 samples, with 30 of 32 variants achieving at least nominally significant associations. The BMI-increasing alleles increased the odds of being overweight by 1.013- to 1.138-fold and the odds of being obese by 1.016- to 1.203-fold (**Supplementary Table 2**). In addition, 30 of the 32 loci also showed directionally consistent effects on the risk of extreme and early-onset obesity in a meta-analysis of seven case-control studies of adults and children (binomial sign test $P = 1.3 \times 10^{-7}$) (**Supplementary Table 3**). The BMI-increasing allele observed in adults also increased the BMI in children and adolescents with directionally consistent effects observed for 23 of the 32 SNPs (binomial sign test $P = 0.01$). Furthermore, in family-based studies, the BMI-increasing allele was over-transmitted to the obese offspring for 24 of the 32 SNPs (binomial sign test $P = 0.004$) (**Supplementary Table 3**). As these studies in extreme obesity cases, children and families were relatively small (with n ranging from 354 to 15,251 individuals) compared to the overall meta-analyses, their power was likely insufficient to confirm association for all 32 loci. Nevertheless, these results show that the effects are unlikely to reflect population stratification and that they extend to BMI differences throughout the life course.

Figure 2 Combined impact of risk alleles on BMI and obesity. **(a)** Combined effect of risk alleles on average BMI in the population-based ARIC study ($n = 8,120$ individuals of European descent). For each individual, the number of 'best guess' replicated ($n = 32$) risk alleles from imputed data (0, 1 or 2) per SNP was weighted for its relative effect size estimated from the stage 2 data. Weighted risk alleles were summed for each individual, and the overall individual sum was rounded to the nearest integer to represent the individual's risk allele score (ranging from 16 to 44). Along the x axis, individuals in each risk allele category are shown (grouped as having ≤ 21 risk alleles and ≥ 38 risk alleles at the extremes), and the mean BMI (\pm s.e.m.) is plotted (y axis on right), with the line representing the regression of the mean BMI values across the risk-allele scores. The histogram (y axis on left) represents the number of individuals in each risk-score category. **(b)** The area under the ROC curve (AUC) of two different models predicting the risk of obesity ($\text{BMI} \geq 30 \text{ kg/m}^2$) in the 8,120 genotyped individuals of European descent in the ARIC study. Model 1, represented by the solid line, includes age, age² and sex (AUC = 0.515, $P = 0.023$ for difference from the null AUC = 0.50). Model 2, represented by the dashed line, includes age, age², sex and the 32 confirmed BMI SNPs (AUC = 0.575, $P < 10^{-5}$ for difference from the null AUC = 0.50). The difference between both AUCs is significant ($P < 10^{-4}$).



All BMI-increasing alleles were associated with increased body weight, as could be expected from the correlation between BMI and body weight (**Supplementary Table 2**). To confirm an effect of the loci on adiposity rather than general body size, we tested for association with body fat percentage, for which data was available in a subset of the stage 2 replication samples ($n = 5,359$ to $n = 28,425$) (**Supplementary Table 2**). The BMI-increasing allele showed directionally consistent effects on body fat percentage at 31 of the 32 confirmed loci (binomial sign test $P = 1.54 \times 10^{-8}$) (**Supplementary Table 2**).

We also examined the association of the BMI loci with metabolic traits (type 2 diabetes¹⁸, fasting glucose, fasting insulin, indices of β -cell function (HOMA-B) and insulin resistance (HOMA-IR)¹⁹, and blood lipid levels²⁰) and with height (**Supplementary Tables 2 and 4**). Although many nominal associations were expected because of known correlations between BMI and most of these traits, and because of overlap in samples, several associations stood out as possible examples of pleiotropic effects of the BMI-associated variants. Particularly interesting is the variant in the *GIPR* locus, where the BMI-increasing allele is also associated with increased fasting glucose levels and lower 2-h glucose levels (**Supplementary Table 4**)^{19,21}. The direction of the effect is opposite to what would be expected due to the correlation between obesity and glucose intolerance but is consistent with the suggested roles of *GIPR* in glucose and energy metabolism (see below)²². Three loci showed strong associations ($P < 10^{-4}$) with height (at *MC4R*, *RBJ-ADCY3-POMC* and *MTCH2-NDUFS3*). Because BMI is weakly correlated with height (and indeed, the BMI-associated variants as a group show no consistent effect on height), these associations are also suggestive of pleiotropy. Notably, analogous to the effects of severe mutations in *POMC* and *MC4R* on height and weight^{23,24}, the BMI-increasing alleles of the variants near these genes were associated with decreased (*POMC*) and increased (*MC4R*) height, respectively (**Supplementary Table 2**).

Potential functional roles and pathway analyses

Although associated variants typically implicate genomic regions rather than individual genes, we note that some of the 32 loci include candidate genes with established connections to obesity. Several of the ten previously identified loci are located in or near genes that encode neuronal regulators of appetite or energy balance, including *MC4R*^{12,25}, *BDNF*²⁶ and *SH2B1*^{11,27}. Each of these genes has been tied to obesity, not only in animal models, but also by rare

human variants that disrupt each of these genes and lead to severe obesity^{24,28,29}. Using the automated literature search program Snipper (Online Methods), we identified various genes within the newly discovered loci with potential biological links to obesity susceptibility (**Supplementary Note**). Among the new loci, the location of rs713586 near *POMC* provides further support for a role of neuroendocrine circuits that regulate energy balance in susceptibility to obesity. *POMC* encodes several polypeptides, including α -MSH, a ligand of the *MC4R* gene product³⁰, and rare mutations in *POMC* also cause obesity in humans^{23,29,31}.

In contrast, the locus near *GIPR*, which encodes a receptor of gastric inhibitory polypeptide (GIP), suggests a role for peripheral biology in obesity. GIP, which is expressed in the K cell of the duodenum and intestine, is an incretin hormone that mediates incremental insulin secretion in response to oral intake of glucose. The variant associated with BMI is in strong LD ($r^2 = 0.83$) with a missense SNP in *GIPR* (rs1800437, p.Glu354Gln) that has recently been shown to influence glucose and insulin response to an oral glucose challenge²¹. Although no human phenotype is known to be caused by mutations in *GIPR*, mice with disruption of *Gipr* are resistant to diet-induced obesity³². The association of a variant in *GIPR* with BMI suggests that there may be a link between incretins, insulin secretion and body weight regulation in humans as well.

To systematically identify biological connections among the genes located near the 32 confirmed SNPs and to potentially identify new pathways associated with BMI, we performed pathway-based analyses using MAGENTA³³. Specifically, we tested for enrichment of genetic associations to BMI in biological processes or molecular functions that contain at least one gene from the 32 confirmed BMI loci (Online Methods). Using annotations from the Kyoto Encyclopedia of Genes and Genomes (KEGG), Ingenuity, Protein Analysis Through Evolutionary Relationships (PANTHER) and Gene Ontology databases, we found evidence of enrichment for pathways involved in platelet-derived growth factor (PDGF) signaling (PANTHER, $P = 0.0008$, false discovery rate (FDR) = 0.0061), translation elongation (PANTHER, $P = 0.0008$, FDR = 0.0066), hormone or nuclear-hormone receptor binding (Gene Ontology, $P < 0.0005$, FDR < 0.0085), homeobox transcription (PANTHER, $P = 0.0001$, FDR = 0.011), regulation of cellular metabolism (Gene Ontology, $P = 0.0002$, FDR = 0.031), neurogenesis and neuron differentiation (Gene Ontology, $P < 0.0002$, FDR < 0.034), protein phosphorylation (PANTHER, $P = 0.0001$, FDR = 0.045)


Figure 3 Regional plots of selected replicating BMI loci with missense and CNV variants. SNPs are plotted by position on the chromosome against association with BMI ($-\log_{10} P$). The SNP name shown on the plot was the most significant SNP after the stage 1 meta-analysis. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. The SNPs surrounding the most significant SNP are color coded to reflect their LD with this SNP (taken from pairwise r^2 values from the HapMap CEU data). Genes, the position of exons and the direction of transcription from the UCSC genome browser are noted. Hashmarks represent SNP positions available in the meta-analysis. (a–c) Missense variants noted with their amino acid change for the gene listed above the plot. (d) Structural haplotypes and the BMI association signal in the *GPRC5B* region. A 21-kb deletion polymorphism was associated with four SNPs ($r^2 = 1.0$) that comprise the best haplogroup associating with BMI. Plots were generated using LocusZoom (see URLs).

and numerous other pathways related to growth, metabolism, immune and neuronal processes (Gene Ontology, $P < 0.002$, FDR < 0.046) (Supplementary Table 5).

Identifying possible functional variants

We used data from the 1000 Genomes Project and the HapMap Consortium to explore whether the 32 confirmed BMI SNPs were in LD ($r^2 \geq 0.75$) with common missense SNPs or copy number variants (CNVs) (Online Methods). Non-synonymous variants in LD with our signals were present in *BDNF*, *SLC39A8*, *FLJ35779-HMGCR*, *QPCTL-GIPR*, *MTCH2*, *ADCY3* and *LBXCOR1*. In addition, the rs7359397 signal was in LD with coding variants in several genes including *SH2B1*, *ATNX2L*, *APOB48R*, *SULT1A2* and *AC138894.2* (Table 1, Fig. 3, Supplementary Table 6 and Supplementary Fig. 2). Furthermore, two SNPs tagged common CNVs. The first CNV has been previously identified⁹ and is a 45-kb deletion near *NEGR1*. The second CNV is a 21-kb deletion that lies 50 kb upstream of *GPRC5B*; the deletion allele is tagged by the T allele of rs12444979 ($r^2 = 1$) (Fig. 3). Although the correlations with potentially functional variants do not prove that these variants are indeed causal, they provide first clues as to which genes and variants at these loci might be prioritized for fine mapping and functional follow up.

Because many of the 32 BMI loci harbor multiple genes, we examined whether gene expression quantitative trait loci (eQTL) analyses could also direct us to positional candidates. Gene expression data were available for human brain, lymphocyte, blood, subcutaneous and visceral adipose tissue, and liver^{34–36} (Online Methods, Table 1 and Supplementary Table 7). Significant *cis* associations, defined at the tissue-specific level, were observed between 14 BMI-associated alleles and expression levels (Table 1 and Supplementary Table 7). In several instances, the BMI-associated SNP was the most significant SNP or explained a substantial proportion of the association with the most significant SNP for the gene transcript in conditional analyses (adjusted $P > 0.05$). These significant associations included *NEGR1*, *ZC3H4*, *TMEM160*, *MTCH2*, *NDUFS3*, *GTF3A*, *ADCY3*, *APOB48R*, *SH2B1*, *TUFM*, *GPRC5B*, *IQCK*, *SLC39A8*, *SULT1A1* and *SULT1A2* (Table 1 and Supplementary Table 7), making these genes higher




priority candidates within the associated loci. However, we note that some BMI-associated variants were correlated with the expression of multiple nearby genes, making it difficult to determine the most relevant gene.

Evidence for the existence of additional associated variants

Because the variants identified by this large study explain only 1.45% of the variance in BMI (2%–4% of genetic variance based on an estimated heritability of 40%–70%), we considered how much the explained phenotypic variance could be increased by including more SNPs at various degrees of significance in a polygene model using an independent validation set (Online Methods)³⁷. We found that including SNPs associated with BMI at lower significance levels (up to $P > 0.05$) increased the explained phenotypic variance in BMI to 2.5%, or 4%–6% of the genetic variance (Fig. 4a). In a separate analysis, we estimated the total number of independent BMI-associated variants that are likely to exist with similar effect sizes as the 32 confirmed here (Online Methods)³⁸. Based on the effect size and allele frequencies of the 32 replicated loci observed in stage 2 and the power to detect association in stage 1 and stage 2 combined, we estimated that there are 284 (95% CI 132–510) loci with similar effect sizes as those currently observed, which together would account for 4.5% (95% CI 3.1%–6.8%) of the phenotypic variation or 6%–11% of the genetic variation in BMI (based on an estimated heritability of 40%–70%) (Supplementary Table 8). In order to detect 95% of these loci, a sample size of approximately 730,000 subjects would be needed (Fig. 4b). This method does not account for the potential of loci of smaller effect than those identified here to explain even more of the variance and thus provides an estimated lower bound of explained variance. These two analyses strongly suggest that larger GWAS will

Figure 4 Phenotypic variance explained by common variants. **(a)** The variance explained is higher when SNPs not reaching genome-wide significance are included in the prediction model. The y axis represents the proportion of variance explained at different P value thresholds from the stage 1 meta-analysis. Results are given for three studies (Rotterdam Study II (RSII), Rotterdam Study III (RSIII), Queens Institute of Medical Research (QIMR)) which were not included in the meta-analysis, after exclusion of all samples from The Netherlands (for RSII and RSIII) and the United Kingdom (for QIMR) from the discovery analysis for this sub-analysis. The dotted line represents the weighted average of the explained variance of three validation sets. **(b)** Cumulative number of susceptibility loci expected to be discovered, including those we have already identified and others that have yet to be detected, by the expected percentage of phenotypic variation explained and the sample size required for a one-stage GWAS assuming a genomic control correction is used. The projections are based on loci that achieved a significance level of $P < 5 \times 10^{-8}$ in the joint analysis of stage 1 and stage 2 and the distribution of their effect sizes in stage 2. The dotted red line corresponds to the expected phenotypic variance explained by the 22 loci that are expected to be discovered in a one-stage GWAS using the sample size of stage 1 of this study.



continue to identify additional new associated loci but also indicate that even extremely large studies focusing on variants with allele frequencies above 5% will not account for a large fraction of the genetic contribution to BMI.

We examined whether selecting only a single variant from each locus for follow up led us to underestimate the fraction of phenotypic variation explained by the associated loci. To search for additional independent loci at each of the 32 associated BMI loci, we repeated our genome-wide association meta-analysis conditioning on the 32 confirmed SNPs. Using a significance threshold of $P = 5 \times 10^{-6}$ for SNPs at known loci, we identified one apparently independent signal at the *MC4R* locus; rs7227255 was associated with BMI ($P = 6.56 \times 10^{-7}$) even after conditioning for the most strongly associated variant near *MC4R* (rs571312) (Fig. 5). Notably, rs7227255 is in perfect LD ($r^2 = 1$) with a relatively rare *MC4R* missense variant (rs2229616, p.Val103Ile, minor allele frequency = 1.7%) that has been associated with BMI in two independent meta-analyses^{39,40}. Furthermore,

mutations at the *MC4R* locus are known to influence early-onset obesity^{24,41}, supporting the notion that allelic heterogeneity may be a frequent phenomenon in the genetic architecture of obesity.

DISCUSSION

Using a two-stage genome-wide association meta-analysis of up to 249,796 individuals of European descent, we identified 18 additional loci that are associated with BMI at genome-wide significance, bringing the total number of such loci to 32. We estimate that more than 250 common variant loci (that is, 284 predicted loci minus 32 confirmed loci) with effects on BMI similar to those described here remain to be discovered and that even larger numbers of loci with smaller effects remain to be identified. A substantial proportion of these loci should be identifiable through larger GWAS and/or by targeted follow up of the top signals selected from our stage 1 analysis. The latter approach is already being implemented through large-scale genotyping of samples informative for BMI using a custom array (the Metabochip) designed to support follow up of thousands of promising variants in hundreds of thousands of individuals.

The combined effect on BMI of the associated variants at the 32 loci is modest, and even when we try to account for as yet undiscovered variants with similar properties, we estimate that these common variant signals account for only 6%–11% of the genetic variation in BMI. There is a strong expectation that additional variance and biology will be explained using complementary approaches that capture variants not examined in the current study, such as lower frequency variants and short insertion-deletion polymorphisms. There is good reason to believe (based on our findings at *MC4R* and other loci, such as those at *POMC*, *BDNF* and *SH2B1*, which feature both common and rare variant associations) that a proportion of such low-frequency and rare causal variation will map to the loci already identified by GWAS.

A primary goal of human genetic discovery is to improve understanding of the biology




Figure 5 A second signal at the *MC4R* locus contributing to BMI. SNPs are plotted by position in a 1-Mb window of chromosome 18 against association with BMI ($-\log_{10} P$). **(a)** Plot highlighting the most significant SNP in the stage 1 meta-analysis. **(b)** Plot highlighting the most significant SNP after conditional analysis, where the model included the most strongly associated SNP as a covariate. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. The SNPs surrounding the most significant SNP are color coded to reflect their LD with this SNP (taken from pairwise r^2 values from the HapMap CEU database). Genes, exons and the direction of transcription from the UCSC genome browser are noted. Hashmarks at the top of the figure represent the positions of SNPs in the meta-analysis. Regional plots were generated using LocusZoom.

of conditions such as obesity⁴². One particularly noteworthy finding in this regard is the association between BMI and common variants near *GIPR*, which may indicate a causal contribution of variation in postprandial insulin secretion in the development of obesity. In most instances, the loci identified by the present study harbor few, if any, annotated genes with clear connections to the biology of weight regulation. This reflects our still limited understanding of the biology of BMI and obesity-related traits and is in striking contrast with the results from equivalent studies of certain other traits (such as autoimmune diseases or lipid levels). Thus, these results suggest that much of the biology that underlies obesity remains to be uncovered and that GWAS may provide an important entry point for investigation. In particular, further examination of the associated loci through a combination of resequencing and fine mapping to find causal variants and genomic and experimental studies designed to assign function could uncover new insights into the biology of obesity.

In conclusion, we performed GWAS in large samples to identify numerous genetic loci associated with variation in BMI, a common measure of obesity. Because current lifestyle interventions are largely ineffective in addressing the challenges of growing obesity^{43,44}, new insights into the biology of obesity are critically needed to guide the development and application of future therapies and interventions.

URLs. LocusZoom, <http://csg.sph.umich.edu/locuszoom/>; METAL, <http://www.sph.umich.edu/csg/abecasis/Metal/>.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

A full list of acknowledgments appears in the **Supplementary Note**.

Funding was provided by Academy of Finland (10404, 77299, 104781, 114382, 117797, 120315, 121584, 124243, 126775, 126925, 127437, 129255, 129269, 129306, 129494, 129680, 130326, 209072, 210595, 213225, 213506 and 216374); ADA Mentor-Based Postdoctoral Fellowship; Amgen; Agency for Science, Technology and Research of Singapore (A*STAR); ALF/LUA research grant in Gothenburg; Althingi (the Icelandic Parliament); AstraZeneca; Augustinus Foundation; Australian National Health and Medical Research Council (241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485 and 613672); Australian Research Council (ARC grant DP0770096); Becket Foundation; Biocenter (Finland); Biomedicum Helsinki Foundation; Boston Obesity Nutrition Research Center; British Diabetes Association (1192); British Heart Foundation (97020; PG/02/128); Busselton Population Medical Research Foundation; Cambridge Institute for Medical Research; Cambridge National Institute of Health Research (NIHR) Comprehensive Biomedical Research Centre; CamStrad (UK); Cancer Research UK; Centre for Medical Systems Biology (The Netherlands); Centre for Neurogenomics and Cognitive Research (The Netherlands); Chief Scientist Office of the Scottish Government; Contrat Plan Etat Région (France); Danish Centre for Health Technology Assessment; Danish Diabetes Association; Danish Heart Foundation; Danish Pharmaceutical Association; Danish Research Council; Deutsche Forschungsgemeinschaft (DFG; HE 1446/4-1); Department of Health (UK); Diabetes UK; Diabetes and Inflammation Laboratory; Donald W. Reynolds Foundation; Dresden University of Technology Funding Grant; Emil and Vera Cornell Foundation; Erasmus Medical Center (Rotterdam); Erasmus University (Rotterdam); European Commission (DG XII; QLG1-CT-2000-01643, QLG2-CT-2002-01254, LSHC-CT-2005, LSHG-CT-2006-018947, LSHG-CT-2004-518153, LSH-2006-037593, LSHM-CT-2007-037273, HEALTH-F2-2008-ENGAGE, HEALTH-F4-2007-201413, HEALTH-F4-2007-201550, FP7/2007-2013, 205419, 212111, 245536, SOC 95201408 05F02 and WLRT-2001-01254); Federal Ministry of Education and Research (Germany) (01AK803, 01EA9401, 01GI0823, 01GI0826, 01GP0209, 01GP0259, 01GS0820, 01GS0823, 01GS0824, 01GS0825, 01GS0830, 01GS0831, 01IG07015, 01KU0903, 01ZZ9603, 01ZZ0103, 01ZZ0403 and 03ZIK012); Federal State of Mecklenburg-West Pomerania; European Social Fund; Eve Appeal; Finnish Diabetes Research Foundation; Finnish Foundation for Cardiovascular Research; Finnish Foundation for Pediatric

Research, Finnish Medical Society; Finska Läkaresällskapet, Päivikki and Sakari Sohlberg Foundation, Folkhälsan Research Foundation; Fond Européen pour le Développement Régional (France); Fondation LeDucq (Paris, France); Foundation for Life and Health in Finland; Foundation for Strategic Research (Sweden); Genetic Association Information Network; German Research Council (KFO-152); German National Genome Research Net 'NGFNplus' (FKZ 01GS0823); German Research Center for Environmental Health; Giorgi-Cavaglieri Foundation; GlaxoSmithKline; Göteborg Medical Society; Great Wine Estates Auctions; Gyllenberg Foundation; Health Care Centers in Vasa, Närpes and Korsholm; Healthway, Western Australia; Helmholtz Center Munich; Helsinki University Central Hospital, Hjärtavärd (the Icelandic Heart Association); INSERM (France); Ib Henriksen Foundation; Interdisziplinäres Zentrum für Klinische Forschung (IZKF) (B27); Jalmari and Rauha Ahokas Foundation; Juho Vainio Foundation; Juvenile Diabetes Research Foundation International (JDRF); Karolinska Institute; Knut and Alice Wallenberg Foundation; Leenaards Foundation; Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LUCAMP); Lundberg Foundation; Marie Curie Intra-European Fellowship; Medical Research Council (UK) (G0000649, G0000934, G9521010D, G0500539, G0600331 and G0601261, PrevMetSyn); Ministry of Cultural Affairs and Social Ministry of the Federal State of Mecklenburg-West Pomerania; Ministry for Health, Welfare and Sports (The Netherlands); Ministry of Education (Finland); Ministry of Education, Culture and Science (The Netherlands); Ministry of Internal Affairs and Health (Denmark); Ministry of Science, Education and Sport of the Republic of Croatia (216-1080315-0302); Ministry of Science, Research and the Arts Baden-Württemberg; Montreal Heart Institute Foundation; Municipal Health Care Center and Hospital in Jakobstad; Municipality of Rotterdam; Närpes Health Care Foundation; National Cancer Institute; National Health and Medical Research Council of Australia; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Oxford Biomedical Research Centre; National Institute for Health Research comprehensive Biomedical Research Centre; US National Institutes of Health (263-MA-410953, AA07535, AA10248, AA014041, AA13320, AA13321, AA13326, CA047988, CA65725, CA87969, CA49449, CA67262, CA50385, DA12854, DK58845, DK46200, DK062370, DK063491, DK072193, HG002651, HL084729, HHSN268200625226C, HL71981, K23-DK080145, K99-HL094535, M01-RR00425, MH084698, N01-AG12100, N01-AG12109, N01-HC15103, N01-HC25195, N01-HC35129, N01-HC45133, N01-HC55015, N01-HC55016, N01-HC55018, N01-HC55019, N01-HC55020, N01-N01HC-55021, N01-HC55022, N01-HC55222, N01-HC75150, N01-HC85079, N01-HC85080, N01-HG-65403, N01-HC85081, N01-HC85082, N01-HC85083, N01-HC85084, N01-HC85085, N01-HC85086, N02-HL64278, P30-DK072488, R01-AG031890, R01-DK073490, R01-DK075787, R01DK068336, R01DK075681, R01-HL59367, R01-HL086694, R01-HL087641, R01-HL087647, R01-HL087652, R01-HL087676, R01-HL087679, R01-HL087700, R01-HL088119, R01-MH59160, R01-MH59565, R01-MH59566, R01-MH59571, R01-MH59586, R01-MH59587, R01-MH59588, R01-MH60870, R01-MH60879, R01-MH61675, R01-MH63706, R01-MH67257, R01-MH79469, R01-MH79470, R01-MH81800, R01-MH083268, U01-CA098233, U01-DK062418, U01-GM074518, U01-HG004402, U01-HG004399, U01-HL72515, U01-HL080295, U01-HL084756, U54-RR020278, T32-HG00040, UL1-RR025005 and Z01-HG000024); National Alliance for Research on Schizophrenia and Depression (NARSAD); Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging (050-060-810); Netherlands Organisation for Scientific Research (NWO) (904-61-090, 904-61-193, 480-04-004, 400-05-717, SPI 56-464-1419, 175.010.2005.011 and 911-03-012); Nord-Trøndelag County Council; Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation; Norwegian Institute of Public Health; Ollqvist Foundation; Oxford NIHR Biomedical Research Centre; Organization for the Health Research and Development (10-000-1002); Paavo Nurmi Foundation; Paul Michael Donovan Charitable Foundation; Perklén Foundation; Petrus and Augusta Hedlunds Foundation; Pew Scholar for the Biomedical Sciences; Public Health and Risk Assessment, Health and Consumer Protection (2004310); Research Foundation of Copenhagen County; Research Institute for Diseases in the Elderly (014-93-015; RIDE2); Robert Dawson Evans Endowment; Royal Society (UK); Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research (CMR, no. A305: 188); Siemens Healthcare, Erlangen, Germany; Sigrid Juselius Foundation; Signe and Ane Gyllenberg Foundation; Science Funding programme (UK); Social Insurance Institution of Finland; Söderberg's Foundation; South Tyrol Ministry of Health; South Tyrolean Sparkasse Foundation; State of Bavaria; Stockholm County Council (560183); Susan G. Komen Breast Cancer Foundation; Swedish Cancer Society; Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Medical Research Council (8691, K2007-66X-20270-01-3, K2010-54X-09894-19-3, K2010-54X-09894-19-3 and 2006-3832); Swedish Research Council; Swedish Society of Medicine; Swiss National Science Foundation

(33CSCO-122661, 310000-112552 and 3100AO-116323/1); Torsten and Ragnar Söderberg's Foundation; Université Henri Poincaré-Nancy 1, Région Lorraine, Communauté Urbaine du Grand Nancy; University Hospital Medical funds to Tampere; University Hospital Oulu, Finland; University of Oulu, Finland (75617); Västra Götaland Foundation; Walter E. Nichols, M.D., and Eleanor Nichols endowments; Wellcome Trust (068545, 072960, 075491, 076113, 077016, 079557, 079895, 081682, 083270, 085301 and 086596); Western Australian DNA Bank; Western Australian Genetic Epidemiology Resource; and Yrjö Jahnsson Foundation.

AUTHOR CONTRIBUTIONS

A full list of author contributions appears in the **Supplementary Note**.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

- Anonymous. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. *Obes. Res.* **6** Suppl 2, 51S–209S (1998); erratum *Obes. Res.* **6**, 464 (1998); comment *Obes. Res.* **6**, 461–462 (1998).
- Lewis, C.E. *et al.* Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. *Circulation* **119**, 3263–3271 (2009).
- Stunkard, A.J., Foch, T.T. & Hrubec, Z. A twin study of human obesity. *J. Am. Med. Assoc.* **256**, 51–54 (1986).
- Maes, H.H., Neale, M.C. & Eaves, L.J. Genetic and environmental factors in relative body weight and human adiposity. *Behav. Genet.* **27**, 325–351 (1997).
- Taylor, A.E. *et al.* Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. *Am. J. Clin. Nutr.* **91**, 547–556 (2010).
- Frayling, T.M. *et al.* A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889–894 (2007).
- Scuteri, A. *et al.* Genome-wide association scan shows genetic variants in the *FTO* gene are associated with obesity-related traits. *PLoS Genet.* **3**, e115 (2007).
- Loos, R.J. *et al.* Common variants near *MC4R* are associated with fat mass, weight and risk of obesity. *Nat. Genet.* **40**, 768–775 (2008).
- Willer, C.J. *et al.* Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat. Genet.* **41**, 25–34 (2009).
- Thorleifsson, G. *et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat. Genet.* **41**, 18–24 (2009).
- Ren, D. *et al.* Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. *J. Clin. Invest.* **117**, 397–406 (2007).
- Huszar, D. *et al.* Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* **88**, 131–141 (1997).
- O'Rahilly, S. & Farooqi, I.S. Human obesity as a heritable disorder of the central control of energy balance. *Int. J. Obes. (Lond)* **32** Suppl 7, S55–S61 (2008).
- Lindgren, C.M. *et al.* Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. *PLoS Genet.* **5**, e1000508 (2009).
- Heard-Costa, N.L. *et al.* *NRXN3* is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. *PLoS Genet.* **5**, e1000539 (2009).
- Meyre, D. *et al.* Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat. Genet.* **41**, 157–159 (2009).
- Scherag, A. *et al.* Two new loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and German study groups. *PLoS Genet.* **6**, e1000916 (2010).
- Zeggini, E. *et al.* Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat. Genet.* **40**, 638–645 (2008).
- Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
- Kathiresan, S. *et al.* Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat. Genet.* **41**, 56–65 (2009).
- Saxena, R. *et al.* Genetic variation in *GIPR* influences the glucose and insulin responses to an oral glucose challenge. *Nat. Genet.* **42**, 142–148 (2010).
- McIntosh, C.H., Widenmaier, S. & Kim, S.J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide, GIP). *Vitam. Horm.* **80**, 409–471 (2009).
- Farooqi, I.S. *et al.* Heterozygosity for a POMC-null mutation and increased obesity risk in humans. *Diabetes* **55**, 2549–2553 (2006).
- Farooqi, I.S. *et al.* Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N. Engl. J. Med.* **348**, 1085–1095 (2003).
- Marsh, D.J. *et al.* Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. *Nat. Genet.* **21**, 119–122 (1999).
- Unger, T.J., Calderon, G.A., Bradley, L.C., Sena-Esteves, M. & Rios, M. Selective deletion of *Bdnf* in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. *J. Neurosci.* **27**, 14265–14274 (2007).
- Li, Z., Zhou, Y., Carter-Su, C., Myers, M.G. Jr. & Rui, L. SH2B1 enhances leptin signaling by both Janus kinase 2 Tyr813 phosphorylation-dependent and -independent mechanisms. *Mol. Endocrinol.* **21**, 2270–2281 (2007).
- Gray, J. *et al.* Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. *Diabetes* **55**, 3366–3371 (2006).
- Bochukova, E.G. *et al.* Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature* **463**, 666–670 (2010).
- Coll, A.P. & Lorraine Tung, Y.C. Pro-opiomelanocortin (POMC)-derived peptides and the regulation of energy homeostasis. *Mol. Cell. Endocrinol.* **300**, 147–151 (2009).
- Krude, H. *et al.* Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4–10. *J. Clin. Endocrinol. Metab.* **88**, 4633–4640 (2003).
- Miyawaki, K. *et al.* Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat. Med.* **8**, 738–742 (2002).
- Segre, A.V. *et al.* Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, e1001058 (2010).
- Emilsson, V. *et al.* Genetics of gene expression and its effect on disease. *Nature* **452**, 423–428 (2008).
- Myers, A.J. *et al.* A survey of genetic human cortical gene expression. *Nat. Genet.* **39**, 1494–1499 (2007).
- Dixon, A.L. *et al.* A genome-wide association study of global gene expression. *Nat. Genet.* **39**, 1202–1207 (2007).
- Purcell, S.M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752 (2009).
- Park, J.-H. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nat. Genet.* **42**, 570–575 (2010).
- Young, E.H. *et al.* The V103I polymorphism of the *MC4R* gene and obesity: population based studies and meta-analysis of 29 563 individuals. *Int. J. Obes. (Lond)* **31**, 1437–1441 (2007).
- Stutzmann, F. *et al.* Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. *Hum. Mol. Genet.* **16**, 1837–1844 (2007).
- Yeo, G.S. *et al.* Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. *Hum. Mol. Genet.* **12**, 561–574 (2003).
- Hirschhorn, J.N. Genomewide association studies—illuminating biologic pathways. *N. Engl. J. Med.* **360**, 1699–1701 (2009).
- Lemmens, V.E., Oenema, A., Klepp, K.I., Henriksen, H.B. & Brug, J. A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. *Obes. Rev.* **9**, 446–455 (2008).
- Anderson, J.W., Konz, E.C., Frederich, R.C. & Wood, C.L. Long-term weight-loss maintenance: a meta-analysis of US studies. *Am. J. Clin. Nutr.* **74**, 579–584 (2001).

Elizabeth K Speliotes^{1,2,250}, Cristen J Willer^{3,250}, Sonja I Berndt^{4,250}, Keri L Monda^{5,250}, Gudmar Thorleifsson^{6,250}, Anne U Jackson³, Hana Lango Allen⁷, Cecilia M Lindgren^{8,9}, Jian'an Luan¹⁰, Reedik Mägi⁸, Joshua C Randall⁸, Sailaja Vedantam^{1,11}, Thomas W Winkler¹², Lu Qi^{13,14}, Tsegaselassie Workalemahu¹³, Iris M Heid^{12,15}, Valgerdur Steinthorsdottir⁶, Heather M Stringham³, Michael N Weedon⁷, Eleanor Wheeler¹⁶, Andrew R Wood⁷, Teresa Ferreira⁸, Robert J Weyant³, Ayellet V Segre^{17–19}, Karol Estrada^{20–22}, Liming Liang^{23,24}, James Nemesh¹⁸,

Ju-Hyun Park⁴, Stefan Gustafsson²⁵, Tuomas O Kilpeläinen¹⁰, Jian Yang²⁶, Nabila Bouatia-Naji^{27,28}, Tõnu Esko^{29–31}, Mary F Feitosa³², Zoltán Kutalik^{33,34}, Massimo Mangino³⁵, Soumya Raychaudhuri^{18,36}, Andre Scherag³⁷, Albert Vernon Smith^{38,39}, Ryan Welch³, Jing Hua Zhao¹⁰, Katja K Aben⁴⁰, Devin M Absher⁴¹, Najaf Amin²⁰, Anna L Dixon⁴², Eva Fisher⁴³, Nicole L Glazer^{44,45}, Michael E Goddard^{46,47}, Nancy L Heard-Costa⁴⁸, Volker Hoesel⁴⁹, Jouke-Jan Hottenga⁵⁰, Åsa Johansson^{51,52}, Toby Johnson^{33,34,53,54}, Shamika Ketkar³², Claudia Lamina^{15,55}, Shengxu Li¹⁰, Miriam F Moffatt⁵⁶, Richard H Myers⁵⁷, Narisu Narisu⁵⁸, John R B Perry⁷, Marjolein J Peters^{21,22}, Michael Preuss⁵⁹, Samuli Ripatti^{60,61}, Fernando Rivadeneira^{20–22}, Camilla Sandholt⁶², Laura J Scott³, Nicholas J Timpson⁶³, Jonathan P Tyrer⁶⁴, Sophie van Wingerden²⁰, Richard M Watanabe^{65,66}, Charles C White⁶⁷, Fredrik Wiklund²⁵, Christina Barlassina⁶⁸, Daniel I Chasman^{69,70}, Matthew N Cooper⁷¹, John-Olov Jansson⁷², Robert W Lawrence⁷¹, Niina Pellikka^{60,61}, Inga Prokopenko^{8,9}, Jianxin Shi⁴, Elisabeth Thiering¹⁵, Helene Alavere²⁹, Maria T S Alibrandi⁷³, Peter Almgren⁷⁴, Alice M Arnold^{75,76}, Thor Aspelund^{38,39}, Larry D Atwood⁴⁸, Beverley Balkau^{77,78}, Anthony J Balmforth⁷⁹, Amanda J Bennett⁹, Yoav Ben-Shlomo⁸⁰, Richard N Bergman⁶⁶, Sven Bergmann^{33,34}, Heike Biebermann⁸¹, Alexandra I F Blakemore⁸², Tanja Boes³⁷, Lori L Bonnycastle⁵⁸, Stefan R Bornstein⁸³, Morris J Brown⁸⁴, Thomas A Buchanan^{66,85}, Fabio Busonero⁸⁶, Harry Campbell⁸⁷, Francesco P Cappuccino⁸⁸, Christine Cavalcanti-Proença^{27,28}, Yii-Der Ida Chen⁸⁹, Chih-Mei Chen¹⁵, Peter S Chines⁵⁸, Robert Clarke⁹⁰, Lachlan Coin⁹¹, John Connell⁹², Ian N M Day⁶³, Martin den Heijer^{93,94}, Jubao Duan⁹⁵, Shah Ebrahim^{96,97}, Paul Elliott^{91,98}, Roberto Elosua⁹⁹, Gudny Eiriksdottir³⁸, Michael R Erdos⁵⁸, Johan G Eriksson^{100–104}, Maurizio F Facheris^{105,106}, Stephan B Felix¹⁰⁷, Pamela Fischer-Posovszky¹⁰⁸, Aaron R Folsom¹⁰⁹, Nele Friedrich¹¹⁰, Nelson B Freimer¹¹¹, Mao Fu¹¹², Stefan Gaget^{27,28}, Pablo V Gejman⁹⁵, Eco J C Geus⁵⁰, Christian Gieger¹⁵, Anette P Gjesing⁶², Anuj Goel^{8,113}, Philippe Goyette¹¹⁴, Harald Grallert¹⁵, Jürgen Gräßler¹¹⁵, Danielle M Greenawalt¹¹⁶, Christopher J Groves⁹, Vilmundur Gudnason^{38,39}, Candace Guiducci¹, Anna-Liisa Hartikainen¹¹⁷, Neelam Hassanali⁹, Alistair S Hall⁷⁹, Aki S Havulinna¹¹⁸, Caroline Hayward¹¹⁹, Andrew C Heath¹²⁰, Christian Hengstenberg^{121,122}, Andrew A Hicks¹⁰⁵, Anke Hinney¹²³, Albert Hofman^{20,22}, Georg Homuth¹²⁴, Jennie Hui^{71,125,126}, Wilmar Igl⁵¹, Carlos Iribarren^{127,128}, Bo Isomaa^{103,129}, Kevin B Jacobs¹³⁰, Ivonne Jarick¹³¹, Elizabeth Jewell³, Ulrich John¹³², Torben Jørgensen^{133,134}, Pekka Jousilahti¹¹⁸, Antti Jula¹³⁵, Marika Kaakinen^{136,137}, Eero Kajantie^{101,138}, Lee M Kaplan^{2,70,139}, Sekar Kathiresan^{17,18,140–142}, Johannes Kettunen^{60,61}, Leena Kinnunen¹⁴³, Joshua W Knowles¹⁴⁴, Ivana Kolcic¹⁴⁵, Inke R König⁵⁹, Seppo Koskinen¹¹⁸, Peter Kovacs¹⁴⁶, Johanna Kuusisto¹⁴⁷, Peter Kraft^{23,24}, Kirsti Kvaløy¹⁴⁸, Jaana Laitinen¹⁴⁹, Olivier Lantieri¹⁵⁰, Chiara Lanzani⁷³, Lenore J Launer¹⁵¹, Cecile Lecoeur^{27,28}, Terho Lehtimäki¹⁵², Guillaume Lettre^{114,153}, Jianjun Liu¹⁵⁴, Marja-Liisa Lokki¹⁵⁵, Mattias Lorentzon¹⁵⁶, Robert N Luben¹⁵⁷, Barbara Ludwig⁸³, MAGIC¹⁵⁸, Paolo Manunta⁷³, Diana Marek^{33,34}, Michel Marre^{159,160}, Nicholas G Martin¹⁶¹, Wendy L McArdle¹⁶², Anne McCarthy¹⁶³, Barbara McKnight⁷⁵, Thomas Meitinger^{164,165}, Olle Melander¹⁶⁶, David Meyre^{27,28}, Kristian Midthjell¹⁴⁸, Grant W Montgomery¹⁶⁷, Mario A Morken⁵⁸, Andrew P Morris⁸, Rosanda Mulic¹⁶⁸, Julius S Ngwa⁶⁷, Mari Nelis^{29–31}, Matt J Neville⁹, Dale R Nyholt¹⁶⁹, Christopher J O'Donnell^{141,170}, Stephen O'Rahilly¹⁷¹, Ken K Ong¹⁰, Ben Oostra¹⁷², Guillaume Paré¹⁷³, Alex N Parker¹⁷⁴, Markus Perola^{60,61}, Irene Pichler¹⁰⁵, Kirsi H Pietiläinen^{175,176}, Carl G P Platou^{148,177}, Ozren Polasek^{145,178}, Anneli Pouta^{117,179}, Suzanne Rafelt¹⁸⁰, Olli Raitakari^{181,182}, Nigel W Rayner^{8,9}, Martin Ridderstråle¹⁶⁶, Winfried Rief¹⁸³, Aimo Ruokonen¹⁸⁴, Neil R Robertson^{8,9}, Peter Rzehak^{15,185}, Veikko Salomaa¹¹⁸, Alan R Sanders⁹⁵, Manjinder S Sandhu^{10,16,157}, Serena Sanna⁸⁶, Jouko Saramies¹⁸⁶, Markku J Savolainen¹⁸⁷, Susann Scherag¹²³, Sabine Schipf^{110,188}, Stefan Schreiber¹⁸⁹, Heribert Schunkert¹⁹⁰, Kaisa Silander^{60,61}, Juha Sinisalo¹⁹¹, David S Siscovick^{45,192}, Jan H Smit¹⁹³, Nicole Soranzo^{16,35}, Ulla Sovio⁹¹, Jonathan Stephens^{194,195}, Ida Surakka^{60,61}, Amy J Swift⁵⁸, Mari-Liis Tammesoo²⁹, Jean-Claude Tardif^{114,153}, Maris Teder-Laving^{30,31}, Tanya M Teslovich³, John R Thompson^{196,197}, Brian Thomson¹, Anke Tönjes^{198,199}, Tiinamaija Tuomi^{103,200,201}, Joyce B J van Meurs^{20–22}, Gert-Jan van Ommen^{202,203}, Vincent Vatin^{27,28}, Jorma Viikari²⁰⁴, Sophie Visvikis-Siest²⁰⁵, Veronique Vitart¹¹⁹, Carla I G Vogel¹²³, Benjamin F Voight^{17–19}, Lindsay L Waite⁴¹, Henri Wallaschofski¹¹⁰, G Bragi Walters⁶, Elisabeth Widen⁶⁰, Susanna Wiegand⁸¹, Sarah H Wild⁸⁷, Gonneke Willemsen⁵⁰, Daniel R Witte²⁰⁶, Jacqueline C Witterman^{20,22}, Jianfeng Xu²⁰⁷, Qunyuan Zhang³², Lina Zgaga¹⁴⁵, Andreas Ziegler⁵⁹, Paavo Zitting²⁰⁸, John P Beilby^{125,126,209}, I Sadaf Farooqi¹⁷¹, Johannes Hebebrand¹²³, Heikki V Huikuri²¹⁰, Alan L James^{126,211}, Mika Kähönen²¹², Douglas F Levinson²¹³, Fabio Macciardi^{68,214}, Markku S Nieminen¹⁹¹, Claes Ohlsson¹⁵⁶, Lyle J Palmer^{71,126}, Paul M Ridker^{69,70}, Michael Stumvoll^{198,215}, Jacques S Beckmann^{33,216}, Heiner Boeing⁴³, Eric Boerwinkle²¹⁷, Dorret I Boomsma⁵⁰, Mark J Caulfield⁵⁴, Stephen J Chanock⁴, Francis S Collins⁵⁸,

L Adrienne Cupples⁶⁷, George Davey Smith⁶³, Jeanette Erdmann¹⁹⁰, Philippe Froguel^{27,28,82}, Henrik Grönberg²⁵, Ulf Gyllensten⁵¹, Per Hall²⁵, Torben Hansen^{62,218}, Tamara B Harris¹⁵¹, Andrew T Hattersley⁷, Richard B Hayes²¹⁹, Joachim Heinrich¹⁵, Frank B Hu^{13,14,23}, Kristian Hveem¹⁴⁸, Thomas Illig¹⁵, Marjo-Riitta Jarvelin^{91,136,137,179}, Jaakko Kaprio^{60,175,220}, Fredrik Karpe^{9,221}, Kay-Tee Khaw¹⁵⁷, Lambertus A Kiemeny^{40,93,222}, Heiko Krude⁸¹, Markku Laakso¹⁴⁷, Debbie A Lawlor⁶³, Andres Metspalu²⁹⁻³¹, Patricia B Munroe⁵⁴, Willem H Ouwehand^{16,194,195}, Oluf Pedersen^{62,223,224}, Brenda W Penninx^{193,225,226}, Annette Peters¹⁵, Peter P Pramstaller^{105,106,227}, Thomas Quertermous¹⁴⁴, Thomas Reinehr²²⁸, Aila Rissanen¹⁷⁶, Igor Rudan^{87,168}, Nilesh J Samani^{180,196}, Peter E H Schwarz²²⁹, Alan R Shuldiner^{112,230}, Timothy D Spector³⁵, Jaakko Tuomilehto^{143,231,232}, Manuela Uda⁸⁶, André Uitterlinden²⁰⁻²², Timo T Valle¹⁴³, Martin Wabitsch¹⁰⁸, Gérard Waeber²³³, Nicholas J Wareham¹⁰, Hugh Watkins^{8,113}, on behalf of Procardis Consortium, James F Wilson⁸⁷, Alan F Wright¹¹⁹, M Carola Zillikens^{21,22}, Nilanjan Chatterjee⁴, Steven A McCarroll¹⁷⁻¹⁹, Shaun Purcell^{17,234,235}, Eric E Schadt^{236,237}, Peter M Visscher²⁶, Themistocles L Assimes¹⁴⁴, Ingrid B Borecki^{32,238}, Panos Deloukas¹⁶, Caroline S Fox²³⁹, Leif C Groop⁷⁴, Talin Haritunians⁸⁹, David J Hunter^{13,14,23}, Robert C Kaplan²⁴⁰, Karen L Mohlke²⁴¹, Jeffrey R O'Connell¹¹², Leena Peltonen^{16,60,61,234,242}, David Schlessinger²⁴³, David P Strachan²⁴⁴, Cornelia M van Duijn^{20,22}, H-Erich Wichmann^{15,185,245}, Timothy M Frayling⁷, Unnur Thorsteinsdottir^{6,246}, Gonçalo R Abecasis³, Inês Barroso^{16,247}, Michael Boehnke^{3,250}, Kari Stefansson^{6,246,250}, Kari E North^{5,248,250}, Mark I McCarthy^{8,9,221,250}, Joel N Hirschhorn^{1,11,249,250}, Erik Ingelsson^{25,250} & Ruth J F Loos^{10,250}

¹Metabolism Initiative and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. ²Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA. ³Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, USA. ⁴Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. ⁵Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. ⁶deCODE Genetics, Reykjavik, Iceland. ⁷Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK. ⁸Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ⁹Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. ¹⁰Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ¹¹Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston, Massachusetts, USA. ¹²Regensburg University Medical Center, Department of Epidemiology and Preventive Medicine, Regensburg, Germany. ¹³Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. ¹⁴Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ¹⁵Institute of Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. ¹⁶Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. ¹⁷Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹⁸Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. ¹⁹Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. ²⁰Department of Epidemiology, Erasmus Medical Center (MC), Rotterdam, The Netherlands. ²¹Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. ²²Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Rotterdam, The Netherlands. ²³Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ²⁴Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA. ²⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ²⁶Queensland Statistical Genetics Laboratory, Queensland Institute of Medical Research, Queensland, Australia. ²⁷Centre National de la Recherche Scientifique (CNRS) UMR8199-IBL-Institut Pasteur de Lille, Lille, France. ²⁸University Lille Nord de France, Lille, France. ²⁹Estonian Genome Center, University of Tartu, Tartu, Estonia. ³⁰Estonian Biocenter, Tartu, Estonia. ³¹Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. ³²Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA. ³³Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland. ³⁴Swiss Institute of Bioinformatics, Lausanne, Switzerland. ³⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ³⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ³⁷Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany. ³⁸Icelandic Heart Association, Kopavogur, Iceland. ³⁹University of Iceland, Reykjavik, Iceland. ⁴⁰Comprehensive Cancer Center East, Nijmegen, The Netherlands. ⁴¹Hudson Alpha Institute for Biotechnology, Huntsville, Alabama, USA. ⁴²Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. ⁴³Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. ⁴⁴Department of Medicine, University of Washington, Seattle, Washington, USA. ⁴⁵Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA. ⁴⁶University of Melbourne, Parkville, Australia. ⁴⁷Department of Primary Industries, Melbourne, Victoria, Australia. ⁴⁸Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. ⁴⁹Technical University Munich, Chair of Biomathematics, Garching, Germany. ⁵⁰Department of Biological Psychology, Vrije Universiteit (VU) University Amsterdam, Amsterdam, The Netherlands. ⁵¹Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden. ⁵²Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. ⁵³Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, London, UK. ⁵⁴Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK. ⁵⁵Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria. ⁵⁶National Heart and Lung Institute, Imperial College London, London, UK. ⁵⁷Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. ⁵⁸National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. ⁵⁹Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. ⁶⁰Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ⁶¹National Institute for Health and Welfare, Department of Chronic Disease Prevention, Unit of Public Health Genomics, Helsinki, Finland. ⁶²Hagedorn Research Institute, Gentofte, Denmark. ⁶³MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, Oakfield House, Bristol, UK. ⁶⁴Department of Oncology, University of Cambridge, Cambridge, UK. ⁶⁵Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. ⁶⁶Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. ⁶⁷Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. ⁶⁸University of Milan, Department of Medicine, Surgery and Dentistry, Milano, Italy. ⁶⁹Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. ⁷⁰Harvard Medical School, Boston, Massachusetts, USA. ⁷¹Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, Western Australia, Australia. ⁷²Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ⁷³University Vita-Salute San Raffaele, Division of Nephrology and Dialysis, Milan, Italy. ⁷⁴Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Malmö, Sweden. ⁷⁵Department of Biostatistics, University of Washington, Seattle, Washington, USA. ⁷⁶Collaborative Health Studies Coordinating Center, Seattle, Washington, USA. ⁷⁷INSERM Centre de recherche en Epidémiologie et Santé des Populations (CESP) Centre for Research in Epidemiology and Public Health U1018, Villejuif, France. ⁷⁸University Paris Sud 11, Unité Mixte de Recherche en Santé (UMRS) 1018, Villejuif, France.

⁷⁹Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK.

⁸⁰Department of Social Medicine, University of Bristol, Bristol, UK. ⁸¹Institute of Experimental Paediatric Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany. ⁸²Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK. ⁸³Department of Medicine III, University of Dresden, Dresden, Germany. ⁸⁴Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ⁸⁵Division of Endocrinology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. ⁸⁶Istituto di Neurogenetica e Neurofarmacologia del Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy. ⁸⁷Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, Scotland, UK. ⁸⁸University of Warwick, Warwick Medical School, Coventry, UK. ⁸⁹Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ⁹⁰Clinical Trial Service Unit, Oxford, UK. ⁹¹Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK. ⁹²University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. ⁹³Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. ⁹⁴Department of Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. ⁹⁵Northshore University Healthsystem, Evanston, Illinois, USA. ⁹⁶The London School of Hygiene and Tropical Medicine, London, UK. ⁹⁷South Asia Network for Chronic Disease, New Delhi, India. ⁹⁸MRC-Health Protection Agency (HPA) Centre for Environment and Health, London, UK. ⁹⁹Cardiovascular Epidemiology and Genetics, Institut Municipal D'investigació Mèdica and Centro de Investigación Biomédica en Red CIBER Epidemiología y Salud Pública, Barcelona, Spain. ¹⁰⁰Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. ¹⁰¹National Institute for Health and Welfare, Helsinki, Finland. ¹⁰²Helsinki University Central Hospital, Unit of General Practice, Helsinki, Finland. ¹⁰³Folkhalsan Research Centre, Helsinki, Finland. ¹⁰⁴Vasa Central Hospital, Vasa, Finland. ¹⁰⁵Institute of Genetic Medicine, European Academy Bozen-Bolzano (EURAC), Bolzano-Bozen, Italy, Affiliated Institute of the University of Lübeck, Lübeck, Germany. ¹⁰⁶Department of Neurology, General Central Hospital, Bolzano, Italy. ¹⁰⁷Department of Internal Medicine B, Ernst-Moritz-Arndt University, Greifswald, Germany. ¹⁰⁸Pediatric Endocrinology, Diabetes and Obesity Unit, Department of Pediatrics and Adolescent Medicine, Ulm, Germany. ¹⁰⁹Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA. ¹¹⁰Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Greifswald, Greifswald, Germany. ¹¹¹Center for Neurobehavioral Genetics, University of California, Los Angeles, California, USA. ¹¹²Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. ¹¹³Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK. ¹¹⁴Montreal Heart Institute, Montreal, Quebec, Canada. ¹¹⁵Department of Medicine III, Pathobiochemistry, University of Dresden, Dresden, Germany. ¹¹⁶Merck Research Laboratories, Merck and Co., Inc., Boston, Massachusetts, USA. ¹¹⁷Department of Clinical Sciences, Obstetrics and Gynecology, University of Oulu, Oulu, Finland. ¹¹⁸National Institute for Health and Welfare, Department of Chronic Disease Prevention, Chronic Disease Epidemiology and Prevention Unit, Helsinki, Finland. ¹¹⁹MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland, UK. ¹²⁰Department of Psychiatry and Midwest Alcoholism Research Center, Washington University School of Medicine, St. Louis, Missouri, USA. ¹²¹Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany. ¹²²Regensburg University Medical Center, Innere Medizin II, Regensburg, Germany. ¹²³Department of Child and Adolescent Psychiatry, University of Duisburg-Essen, Essen, Germany. ¹²⁴Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany. ¹²⁵PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII Medical Centre, Nedlands, Western Australia, Australia. ¹²⁶Busselton Population Medical Research Foundation Inc., Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ¹²⁷Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. ¹²⁸Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA. ¹²⁹Department of Social Services and Health Care, Jakobstad, Finland. ¹³⁰Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute (NCI)-Frederick, Frederick, Maryland, USA. ¹³¹Institute of Medical Biometry and Epidemiology, University of Marburg, Marburg, Germany. ¹³²Institut für Epidemiologie und Sozialmedizin, Universität Greifswald, Greifswald, Germany. ¹³³Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. ¹³⁴Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark. ¹³⁵National Institute for Health and Welfare, Department of Chronic Disease Prevention, Population Studies Unit, Turku, Finland. ¹³⁶Institute of Health Sciences, University of Oulu, Oulu, Finland. ¹³⁷Biocenter Oulu, University of Oulu, Oulu, Finland. ¹³⁸Hospital for Children and Adolescents, Helsinki University Central Hospital and University of Helsinki, Hospital District of Helsinki and Uusimaa (HUS), Helsinki, Finland. ¹³⁹Massachusetts General Hospital (MGH) Weight Center, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹⁴⁰Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹⁴¹Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University, Framingham, Massachusetts, USA. ¹⁴²Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. ¹⁴³National Institute for Health and Welfare, Diabetes Prevention Unit, Helsinki, Finland. ¹⁴⁴Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. ¹⁴⁵Andrija Stampar School of Public Health, Medical School, University of Zagreb, Zagreb, Croatia. ¹⁴⁶Interdisciplinary Centre for Clinical Research, University of Leipzig, Leipzig, Germany. ¹⁴⁷Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland. ¹⁴⁸Nord-Trøndelag Health Study (HUNT) Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway. ¹⁴⁹Finnish Institute of Occupational Health, Oulu, Finland. ¹⁵⁰Institut inter-régional pour la santé (IRSA), La Riche, France. ¹⁵¹Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA. ¹⁵²Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Tampere, Finland. ¹⁵³Department of Medicine, Université de Montréal, Montreal, Quebec, Canada. ¹⁵⁴Human Genetics, Genome Institute of Singapore, Singapore, Singapore. ¹⁵⁵Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland. ¹⁵⁶Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ¹⁵⁷Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, UK. ¹⁵⁸On behalf of the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits Consortium) investigators. ¹⁵⁹Department of Endocrinology, Diabetology and Nutrition, Bichat-Claude Bernard University Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France. ¹⁶⁰Cardiovascular Genetics Research Unit, Université Henri Poincaré-Nancy 1, Nancy, France. ¹⁶¹Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland, Australia. ¹⁶²Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, Department of Social Medicine, University of Bristol, Bristol, UK. ¹⁶³Division of Health, Research Board, An Bord Taighde Sláinte, Dublin, Ireland. ¹⁶⁴Institute of Human Genetics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. ¹⁶⁵Institute of Human Genetics, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany. ¹⁶⁶Department of Clinical Sciences, Lund University, Malmö, Sweden. ¹⁶⁷Molecular Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland, Australia. ¹⁶⁸Croatian Centre for Global Health, School of Medicine, University of Split, Split, Croatia. ¹⁶⁹Neurogenetics Laboratory, Queensland Institute of Medical Research, Queensland, Australia. ¹⁷⁰National Heart, Lung, and Blood Institute, National Institutes of Health, Framingham, Massachusetts, USA. ¹⁷¹University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ¹⁷²Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands. ¹⁷³Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. ¹⁷⁴Amgen, Cambridge, Massachusetts, USA. ¹⁷⁵Finnish Twin Cohort Study, Department of Public Health, University of Helsinki, Helsinki, Finland. ¹⁷⁶Obesity Research Unit, Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland. ¹⁷⁷Department of Medicine, Levanger Hospital, The Nord-Trøndelag Health Trust, Levanger, Norway. ¹⁷⁸Gen-Info Ltd, Zagreb, Croatia. ¹⁷⁹National Institute for Health and Welfare, Oulu, Finland. ¹⁸⁰Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK. ¹⁸¹Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland. ¹⁸²The Department of Clinical Physiology, Turku University Hospital, Turku, Finland. ¹⁸³Clinical Psychology and Psychotherapy, University of Marburg, Marburg, Germany. ¹⁸⁴Department of Clinical Sciences and Clinical Chemistry, University of Oulu, Oulu, Finland. ¹⁸⁵Ludwig-Maximilians-Universität, Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Munich, Germany. ¹⁸⁶South Karelia Central Hospital, Lappeenranta, Finland. ¹⁸⁷Department of Clinical Sciences and Internal Medicine, University of Oulu, Oulu, Finland. ¹⁸⁸Institut für Community Medicine, Greifswald, Germany. ¹⁸⁹Christian-Albrechts-University, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology and Department of Internal Medicine I, Kiel, Germany. ¹⁹⁰Universität zu Lübeck, Medizinische Klinik II, Lübeck, Germany. ¹⁹¹Division of Cardiology, Cardiovascular Laboratory, Helsinki University Central Hospital, Helsinki, Finland. ¹⁹²Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, USA. ¹⁹³Department of Psychiatry, Instituut voor Extramuraal Geneeskundig Onderzoek (EMGO) Institute, VU University Medical Center, Amsterdam, The Netherlands. ¹⁹⁴Department of Haematology, University of Cambridge, Cambridge, UK. ¹⁹⁵National Health Service (NHS) Blood and Transplant, Cambridge Centre, Cambridge, UK. ¹⁹⁶Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK. ¹⁹⁷Department of Health Sciences, University of Leicester, University Road, Leicester, UK. ¹⁹⁸Department of Medicine, University of Leipzig, Leipzig, Germany. ¹⁹⁹Coordination Centre for Clinical Trials, University of Leipzig, Leipzig, Germany. ²⁰⁰Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland. ²⁰¹Research Program of Molecular Medicine, University of Helsinki, Helsinki, Finland. ²⁰²Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. ²⁰³Center of Medical Systems Biology, Leiden University Medical Center, Leiden, The Netherlands. ²⁰⁴Department of Medicine, University of Turku and Turku University Hospital, Turku, Finland. ²⁰⁵INSERM

Cardiovascular Genetics team, Centre Investigation Clinique (CIC) 9501, Nancy, France. ²⁰⁶Steno Diabetes Center, Gentofte, Denmark. ²⁰⁷Center for Human Genomics, Wake Forest University, Winston-Salem, North Carolina, USA. ²⁰⁸Department of Psychiatrics, Lapland Central Hospital, Rovaniemi, Finland. ²⁰⁹School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Western Australia, Australia. ²¹⁰Department of Internal Medicine, University of Oulu, Oulu, Finland. ²¹¹School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. ²¹²Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland. ²¹³Stanford University School of Medicine, Stanford, California, USA. ²¹⁴Department of Psychiatry and Human Behavior, University of California, Irvine (UCI), Irvine, California, USA. ²¹⁵Leipziger Interdisziplinärer Forschungs-komplex zu molekularen Ursachen umwelt- und lebensstilassoziierter Erkrankungen (LIFE) Study Centre, University of Leipzig, Leipzig, Germany. ²¹⁶Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, Lausanne, Switzerland. ²¹⁷Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA. ²¹⁸Faculty of Health Science, University of Southern Denmark, Odense, Denmark. ²¹⁹New York University Medical Center, New York, New York, USA. ²²⁰National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Unit for Child and Adolescent Mental Health, Helsinki, Finland. ²²¹NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK. ²²²Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. ²²³Institute of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. ²²⁴Faculty of Health Science, University of Aarhus, Aarhus, Denmark. ²²⁵Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands. ²²⁶Department of Psychiatry, University Medical Centre Groningen, Groningen, The Netherlands. ²²⁷Department of Neurology, University of Lübeck, Lübeck, Germany. ²²⁸Institute for Paediatric Nutrition Medicine, Vestische Hospital for Children and Adolescents, University of Witten-Herdecke, Datteln, Germany. ²²⁹Department of Medicine III, Prevention and Care of Diabetes, University of Dresden, Dresden, Germany. ²³⁰Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland, USA. ²³¹Hjelt Institute, Department of Public Health, University of Helsinki, Helsinki, Finland. ²³²South Ostrobothnia Central Hospital, Seinajoki, Finland. ²³³Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, Lausanne, Switzerland. ²³⁴The Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA. ²³⁵Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA. ²³⁶Pacific Biosciences, Menlo Park, California, USA. ²³⁷Sage Bionetworks, Seattle, Washington, USA. ²³⁸Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA. ²³⁹Division of Intramural Research, National Heart, Lung, and Blood Institute, Framingham Heart Study, Framingham, Massachusetts, USA. ²⁴⁰Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, New York, USA. ²⁴¹Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA. ²⁴²Department of Medical Genetics, University of Helsinki, Helsinki, Finland. ²⁴³Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland, USA. ²⁴⁴Division of Community Health Sciences, St. George's, University of London, London, UK. ²⁴⁵Klinikum Grosshadern, Munich, Germany. ²⁴⁶Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ²⁴⁷University of Cambridge Metabolic Research Labs, Institute of Metabolic Science Addenbrooke's Hospital, Cambridge, UK. ²⁴⁸Carolina Center for Genome Sciences, School of Public Health, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA. ²⁴⁹Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. ²⁵⁰These authors contributed equally to this work. Correspondence should be addressed to M.B. (boehnke@umich.edu), K. Stefansson (kstefans@decode.is), K.E.N. (kari_north@unc.edu), M.I.M. (mark.mccarthy@drl.ox.ac.uk), J.N.H. (joelh@broadinstitute.org), E.I. (erik.ingelsson@ki.se) or R.J.F.L. (ruth.loos@mrc-epid.cam.ac.uk).

ONLINE METHODS

Study design. We designed a multistage study (**Supplementary Fig. 1**) comprising a genome-wide association meta-analysis (stage 1) of data on up to 123,865 genotyped individuals from 46 studies and selected 42 SNPs with $P < 5 \times 10^{-6}$ for follow up in stage 2. Stage 2 comprised up to 125,931 additional genotyped individuals from 42 studies. Meta-analysis of stage 1 and stage 2 summary statistics identified 32 SNPs that reached genome-wide significance ($P < 5 \times 10^{-8}$).

Stage 1 genome-wide association meta-analysis. Samples and genotyping. The GIANT consortium currently encompasses 46 studies with up to 123,865 genotyped adult individuals of European ancestry with data on BMI (**Supplementary Note**). The samples from 46 studies, including between 276 and 26,799 individuals each, were genotyped using Affymetrix and Illumina whole genome genotyping arrays (**Supplementary Note**). To allow for meta-analysis across different marker sets, imputation of polymorphic HapMap European CEU SNPs (**Supplementary Note**) was performed using MACH⁴⁵, IMPUTE⁴⁶ or BimBam⁴⁷.

Association analysis with BMI. Each study performed single marker association analyses with BMI using an additive genetic model implemented in MACH2QTL (Y. Li, C.J.W., P.S. Ding and G.R.A., unpublished data), Merlin⁴⁸, SNPTEST⁴⁶, ProbABEL⁴⁹, GenABEL⁵⁰, LME in R or PLINK⁵¹. BMI was adjusted for age, age² and other appropriate covariates (for example, principal components) and inverse normally transformed to a mean of 0 and a standard deviation of 1. Analyses were stratified by sex and case status (for samples ascertained for other diseases) (**Supplementary Note**). To allow for relatedness in the SardiNIA, Framingham Heart, Amish HAPI Heart and Family Heart studies, regression coefficients were estimated in the context of a variance component model that modeled relatedness in men and women combined with sex as a covariate. Before meta-analyzing the genome-wide association data for the 46 studies, SNPs with poor imputation quality scores (r^2 .hat < 0.3 in MACH, observed/expected dosage variance < 0.3 in BimBam or proper_info < 0.4 in IMPUTE) and those with a minor allele count (MAC = $2 \times N \times$ minor allele frequency) of < 6 in each sex- and case-specific stratum were excluded for each study. All individual GWAS were genomic control corrected before meta-analysis. Individual study-specific genomic control values ranged from 0.983 to 1.104 (**Supplementary Note**).

Meta-analysis of stage 1 association results. Next, we performed the stage 1 meta-analysis using the inverse variance method, which is based on β values and standard errors from each individual GWAS. To ensure consistency of results, we also performed the stage 1 meta-analysis using the weighted z-score method, which is based on the direction of association and P values of each of the individual studies. Both meta-analyses were performed using METAL (see URLs), and the correlation between the resulting $-\log_{10} P$ values was high ($r > 0.99$). For the discovery of replicating variants, the results of the inverse variance meta-analysis were used followed by a final genomic control correction of the meta-analyzed results. The genomic control value for the meta-analyzed results before genomic control correction was 1.318.

Selection of SNPs for follow up. Forty-two lead SNPs, representing the forty-two most significant ($P < 5 \times 10^{-6}$) independent loci, were selected for replication analyses (stage 2) (**Supplementary Table 1**). Loci were considered independent when separated by at least 1 Mb. For some loci, the SNP with the strongest association could not be genotyped for technical reasons and was substituted by a proxy SNP that was in high LD with it ($r^2 > 0.8$) according to the HapMap CEU data (**Supplementary Table 1**). We tested the association of these 42 SNPs in 16 *de novo* and 18 *in silico* replication studies in stage 2.

Stage 2 follow up. Samples and genotyping. Directly genotyped data for the 42 SNPs was available from a total of 79,561 adults of European ancestry from 16 studies using Sequenom iPLEX or TaqMan assays (**Supplementary Note**). Samples and SNPs that did not meet the quality control criteria defined by each individual study were excluded. Minimum genotyping quality control criteria were defined as Hardy-Weinberg Equilibrium $P > 10^{-6}$, call rate > 90%

and concordance > 99% in duplicate samples in each of the follow-up studies. Association results were also obtained for the 42 most significant SNPs from 46,370 individuals of European ancestry from 18 GWAS that had not been included in the stage 1 analyses (**Supplementary Note**). Studies included between 345 and 22,888 individuals and were genotyped using Affymetrix and Illumina genome-wide genotyping arrays. Autosomal HapMap SNPs were imputed using either MACH⁴⁵ or IMPUTE⁴⁶. SNPs with poor imputation quality scores from the *in silico* studies (r^2 .hat < 0.3 in MACH or proper_info < 0.4 in IMPUTE), and SNPs with a MAC < 6 in each sex- and case-specific stratum were excluded.

Association analyses and meta-analysis. We tested the association between the 42 SNPs and BMI in each *in silico* and *de novo* stage 2 study separately as described for the stage 1 studies. We subsequently meta-analyzed β values and standard errors from the stage 2 studies using the inverse-variance method. The meta-analysis using a weighted z-score method was similar (the r between P values was > 0.99) and included up to 249,796 individuals. Data was available for at least 179,000 individuals for 41 of the 42 SNPs. For one SNP (rs6955651 in KIAA1505), data was only available for 125,672 individuals due to technical challenges relating to the genotyping and imputation of this SNP. Next, we meta-analyzed the summary statistics of the stage 1 and stage 2 meta-analyses using the inverse-variance method in METAL.

Assessment of population stratification. To assess for possible inflation of test statistics by population stratification, we performed a family-based analysis, which is immune to stratification, in 5,507 individuals with pedigree information from the Framingham Heart Study using that the QFAM-within procedure in PLINK. Effect sizes and directions in the Framingham Heart Study data are the β statistics reported by PLINK from the within-family analysis, and the P values are empirical and are based on permutation testing. For imputed SNPs, only those with r^2 .hat > 0.3 in MACH were analyzed using the best-guess genotypes from dosages reported by MACH. For the 32 loci in general and the 18 new loci in particular, the estimated effect sizes on BMI were essentially identical in the overall meta-analysis and in the Framingham Heart Study sample (**Supplementary Note**), and, as expected in the absence of substantial stratification, about half of the loci (18 out of 32 loci total and 10 out of 18 new loci) had a larger effect size in the family-based sample. These results indicate that the genome-wide significant associations in our meta-analysis are not substantially confounded by stratification.

In addition, we estimated the fixation index (Fst) for all SNPs to test whether the 32 confirmed BMI SNPs might be false-positive results due to population stratification. We selected five diverse European populations with relatively large sample sizes (Northern Finland Birth Cohort (NFBC), British 1958 Birth Cohort, SardiNIA, CoLaus and DeCODE) for this analysis. The mean Fst value for the 32 confirmed BMI SNPs was not significantly different from the mean Fst for 2.1 million non-BMI associated SNPs (t test $P = 0.28$), suggesting that the SNPs that are associated with BMI do not appear to have strong allele frequency differences across the European samples examined.

Follow-up analyses. Subsequently, we performed an extensive series of follow-up analyses to estimate the impact of the 32 confirmed BMI loci in adults and children and to explore their potential functional roles. These follow-up analyses are described in detail in the **Supplementary Note**.

In brief, we estimated the cumulative effect of the 32 loci combined on BMI and assessed their predictive ability in obesity and BMI in the ARIC study. Association between the 32 confirmed BMI variants and overweight or obese status was assessed in stage 2 samples, and association with BMI in children and adolescents was examined in four population-based studies. Furthermore, we tested for association between the 32 SNPs and extreme or early-onset obesity in seven case-control studies of extremely obese adults and extremely obese children or adolescents. Data on the association between the 32 SNPs and height and weight were obtained from the stage 2 replication samples, and data on the association with related traits were extracted from previously reported genome-wide association meta-analyses for type 2 diabetes (Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium¹⁸), lipid levels (the Global Lipids

Genetics Consortium²⁰) and glycemetic traits (Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC)^{19,21}).

To discover potentially new pathways associated with BMI, we tested whether predefined biological processes or molecular functions that contain at least one gene within 300 kb of the 32 confirmed BMI SNPs were enriched for multiple modest BMI associations using MAGENTA³³. We identified SNPs having $r^2 \geq 0.75$ with the lead SNP that were likely non-synonymous, nonsense or which occurred within 5 bp of the exon-intron boundary and also evaluated whether any of the 32 confirmed BMI SNPs tagged common CNVs. We examined the *cis* associations between each of the 32 confirmed BMI SNPs and expression of nearby genes in adipose tissue^{34,52}, whole blood³⁴, lymphocytes^{36,52} and brain³⁵.

We evaluated the amount of phenotypic variance explained by the 32 BMI loci using a method proposed by the International Schizophrenia Consortium³⁷ and estimated the number of susceptibility loci that are likely to exist using a new method³⁸ based on the distribution of effect sizes and minor allele frequencies observed for the established BMI loci and the power to detect those effects in the combined stage 1 and stage 2 analysis.

We performed a conditional genome-wide association analysis to examine whether any of the 32 confirmed BMI loci harbored additional independent

signals, and we also examined gene-by-gene and gene-by-sex interactions among the BMI loci. Dominant and recessive analyses were performed for the 32 confirmed BMI SNPs to test for non-additive effects.

45. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. *Annu. Rev. Genomics Hum. Genet.* **10**, 387–406 (2009).
46. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913 (2007).
47. Guan, Y. & Stephens, M. Practical issues in imputation-based association mapping. *PLoS Genet.* **4**, e1000279 (2008).
48. Abecasis, G.R. & Wigginton, J.E. Handling marker-marker linkage disequilibrium: pedigree analysis with clustered markers. *Am. J. Hum. Genet.* **77**, 754–767 (2005).
49. Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics* **11**, 134 (2010).
50. Aulchenko, Y.S., Ripke, S., Isaacs, A. & van Duijn, C.M. GenABEL: an R library for genome-wide association analysis. *Bioinformatics* **23**, 1294–1296 (2007).
51. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
52. Zhong, H., Yang, X., Kaplan, L.M., Molony, C. & Schadt, E.E. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. *Am. J. Hum. Genet.* **86**, 581–591 (2010).